The data presented in this paper demonstrated that an inherited physiologic driver of prostate cancer mortality, adrenal-permissive HSD3B1 genotype, which has been shown to be associated with poorer clinical outcomes in nonmetastatic HSPC and mHSPC, is potentially pharmacologically reversible with potent AR antagonism. This evidence concerns the gene AR and Familial prostate cancer.